Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation

NCT03097796 is registered in ClinicalTrials.gov with Pulmotect, Inc. as lead sponsor.

NCT NCT03097796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03097796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation
Lead sponsor
Pulmotect, Inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2024
Completion date
May 31, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic diseases, stem cell transplants